Please assess the completion status of the following clinical trial:

Trial Title: E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion:≥ 18 years of age~* Treated with maintenance hemodialysis - PTH ≥ 300 pg/mL (31.8 pmol/L)~* serum calcium ≥ 8.4mg/dL (2.1 mmol/L)~* Ca x P ≥ 45 mg2\*/dL2 (3.63 mmol2/L2)~Exclusion Criteria: - Exclusion:~* Parathyroidectomy in the 12 weeks before the date of informed consent~* Received therapy with cinacalcet within 3 months of randomization~* Hospitalization within 12 weeks of randomization for any of the following events: a. Myocardial ischemia b. Unstable angina c. Heart Failure (HF) (including any unplanned presentation to a health care facility that would require mechanical intervention \[i.e., unplanned dialysis treatment\]) d. Peripheral vascular disease (other than dialysis vascular access revision) e. Stroke~* History of seizure within 12 weeks prior to randomization~* Scheduled date for kidney transplant from a known living donor~* Anticipated parathyroidectomy within 6 months after randomization~  * in all instances, the 2 refers to squared.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cinacalcet (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).